Figure 1: cotreatment tazarotene at variable concentrations + IFN-a (100U/ml) in SK-BR-3 cells

% BrdU Incorporation

Concentration (10^x M)

Legend:
- —♦— tazarotene
- ····■···· Theoretical combination curve calculated for additivity
- —▲— Experimental combination curve: tazarotene + IFN-a 100 U/ml

Figure 2: cotreatment tazarotene at variable concentrations + IFN-a (100U/ml) in T-47D cells

Legend:
- —♦— tazarotene
- ....■.... Theoretical combination curve calculated for additivity
- —▲— Experimental combination curve: tazarotene + IFN-a 100 U/ml

X-axis: Concentration (10^x M)
Y-axis: % BrdU Incorporation

Figure 3: cotreatment tazarotene at variable concentrations + IFN-b (10 U/ml) in SK-BR-3 cells

Figure 4: cotreatment tazarotene at variable concentrations + IFN-b (100 U/ml) in T-47D cells

Figure 5: cotreatment tazarotene at variable concentrations + IFN-g (100 U/ml) in SK-BR-3 cells

Legend:
— tazarotene
- - ■ - - Theoretical combination curve calculated for additivity
—▲— Experimental combination curve: tazarotene + IFN-g 100 U/ml

Figure 6: cotreatment tazarotene at variable concentrations + IFN-g (100 U/ml) in T-47D cells

Legend:
- ◆— tazarotene
- ■·· Theoretical combination curve calculated for additivity
- ▲— Experimental combination curve: tazarotene + IFN-g 100 U/ml

Figure 7: cotreatment IFN-a at variable concentrations + tazarotene (10 nM) in SK-BR-3 cells

% BrdU Incorporation (y-axis)

Concentration (10^x M) (x-axis)

Legend:
- IFN-a
- Theoretical combination curve calculated for additivity
- Experimental combination curve: IFN-a + tazarotene 10 nM

Figure 8: cotreatment IFN-a at variable concentrations + tazarotene (10 nM) in T-47D cells

Legend:
- IFN-a
- Theoretical combination curve calculated for additivity
- Experimental combination curve: IFN-a + tazarotene 10 nM

Axis: % BrdU Incorporation (0, 20, 40, 60, 80, 100, 120)

Concentration (10^x M) (0, 200, 400, 600, 800, 1000)

Figure 9: cotreatment IFN-b at variable concentrations + tazarotene (10 nM) in SK-BR-3 cells

Figure 10: cotreatment IFN-b at variable concentrations + tazarotene (10 nM) in T-47D cells

Legend:
- IFN-b
- Theoretical combination curve calculated for additivity
- Experimental combination curve: IFN-b + tazarotene 10 nM

% BrdU Incorporation

Concentration (10 × M)

% BrdU Incorporation

Figure 11: cotreatment IFN-g at variable concentrations + tazarotene (10 nM) in SK-BR-3 cells

Concentration (10^x M)

Legend:
- ◆ IFN-g
- ▨ Theoretical combination curve calculated for additivity
- ▨ Experimental combination curve: IFN-g + tazarotene 10 nM

Figure 12: cotreatment IFN-g at variable concentrations + tazarotene (10 nM) in T-47D cells

% BrdU Incorporation (y-axis: 0, 20, 40, 60, 80, 100, 120, 140)

Concentration (10 × M) (x-axis: 0, 200, 400, 600, 800, 1000)

Legend:
- ◆ IFN-g
- ■ Theoretical combination curve calculated for additivity
- ▲ Experimental combination curve: IFN-g + tazarotene 10 nM

Figure 13: Cotreatment tazarotene at variable concentrations + IFN-alpha (100U/ml) in HL-60

% Viable cells relative to control

Concentration (10^x M)

Legend:
- Tazarotene
- Theoretical combination curve calculated for additivity
- Experimental combination curve: Tazarotene + IFN-a 100 U/ml

Figure 14: Cotreatment tazarotene at variable concentrations + IFN-beta (100U/ml) in HL-60

Figure 15: Cotreatment IFN-alpha at variable concentrations + tazarotene (50nM) in HL-60

% Viable cells relative to control

Concentration (10^x M)

Legend:
- IFN-alpha
- Theoretical combination curve calculated for additivity
- Experimental combination curve: IFN-a + Tazarotene 50 nM

*

**

Figure 16: Cotreatment IFN-beta at variable concentrations + tazarotene (50nM) in HL-60

% Viable cells relative to control (y-axis: 0, 20, 40, 60, 80, 100, 120)

Concentration (10^x M) (x-axis: 0, 200, 400, 600, 800, 1000)

Legend:
- ◆— IFN-b
- ■···· Theoretical combination curve calculated for additivity
- ▲— Experimental combination curve: IFN-b + Tazarotene 50 nM